ELTX — Elicio Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $87.74m
- $90.16m
Annual income statement for Elicio Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.88 | 28.3 | 2.3 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 1.69 | 27.9 | 2.3 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 58.2 | 66.7 | 41.9 | 35.1 | 45 |
| Operating Profit | -55.3 | -38.4 | -39.6 | -35.1 | -45 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -80.1 | -54.6 | -38.8 | -35.2 | -51.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -80.1 | -54.6 | -38.8 | -35.2 | -51.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -80.1 | -54.6 | -38.8 | -35.2 | -51.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -80.1 | -54.6 | -38.8 | -35.2 | -51.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -54.2 | -19.6 | -9.86 | -7.08 | -4.25 |